@article{19c4d2fed8e141e7bf7cfae2fc0cb0b4,
title = "Drug utilization in the Maastricht Study: A comparison with nationwide data",
abstract = "Within the southern region of the Netherlands, the Maastricht Study is an on-going observational prospective population-based cohort study that focuses on the etiology of Type 2 diabetes mellitus (T2DM). Representativeness of the participating population is a crucial but often an unknown factor in population-based cohort studies such as the Maastricht Study. We therefore aimed to assess the representativeness of the study population by comparing drug utilization of the participants of the Maastricht Study with the general population of the Netherlands.Since T2DM patients were oversampled in this study, a sampling method was applied in order to ensure a similar distribution of T2DM over the study population. Drug use in the study population was compared with drug use in the population of the Netherlands, using a Z-test to compare 2 independent proportions.In general, drug use in the study was similar compared with national data. However, in the age group 65 to 74 years total drug use was lower in the study population (833/1000 persons) versus nationwide data (882/1000 persons). The use of pulmonary medications was lower (104/1000 persons vs 141/1000 persons) and the use of hypnotics/anxiolytics was higher (90/1000 persons vs 36/1000 persons) in the Maastricht Study as compared with national data.Drug use in the Maastricht Study population is largely comparable to that in the total Dutch population aged 45 to 74. Therefore, data on drug use by participants in the Maastricht Study can be used to perform studies assessing outcomes associated with drug use.",
keywords = "Aged, Anti-Anxiety Agents/therapeutic use, Diabetes Mellitus, Type 2/drug therapy, Drug Utilization/statistics & numerical data, Female, Humans, Hypnotics and Sedatives/therapeutic use, Male, Middle Aged, Netherlands/epidemiology, Population Health/statistics & numerical data, Prospective Studies, Respiratory System Agents/therapeutic use, drug utilization, RISK, DIABETES-MELLITUS, epidemiology, participation bias, type 2 diabetes, Maastricht Study, PARTICIPATION",
author = "Nielen, {Johannes T H} and Driessen, {Johanna H M} and Dagnelie, {Pieter C} and Annelies Boonen and {van den Bemt}, Bart and {van Onzenoort}, {Hein A W} and Cees Neef and Henry, {Ronald M A} and Burden, {Andrea M} and Sep, {Simone J S} and {van der Kallen}, {Carla J} and Schram, {Miranda T} and Nicolaas Schaper and Stehouwer, {Coen D A} and Luc Smits and {de Vries}, Frank",
note = "Funding Information: The Maastricht Study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31O.041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), the Cardiovascular Center (CVC, Maastricht, the Netherlands), CARIM School for Cardiovascular Diseases (Maastricht, the Netherlands), CAPHRI School for Public Health and Primary Care (Maastricht, the Netherlands), NUTRIM School for Nutrition and Translational Research in Metabolism (Maas-tricht, the Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands), and by unrestricted grants from Janssen-Cilag B. V. (Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, the Netherlands), and Sanofi-Aventis Netherlands B.V. (Gouda, the Netherlands). We thank all participants of the Maastricht Study, their community pharmacists, the Apothekers Vereniging Maastricht, and the Verenigde Apotheken Limburg for their cooperation. Funding Information: JTHN and JHMD are co-first authors and have equally contributed to the manuscript. Data sharing: No additional data available. BB receives research grants to his department from Pfizer and Roche and occasionally speakers honoraria form Pfizer, Roche, Abbvie, and MSD. AB receives research grants to her department from Amgen Abbvie, Pfizer, and Merck and occasionally speakers honoraria from Pfizer, UCB, Janssen, and Sandoz. PE receives research grants to his department from Stryker, Active implants, Carbylan Biosurgery, DSM Biomedical, Regentis, and occasionally speakers honoraria from Biomet and Push braces. PD has received unrestricted grants from NWO, EU, and nutritional industry for research unrelated to this topic. AMB is supported by a Canadian Institutes of Health Research (CIHR) Post-Doctoral Fellowship. All other authors have no conflicts of interest to declare. Publisher Copyright: {\textcopyright} 2020 the Author(s). Published by Wolters Kluwer Health, Inc.",
year = "2020",
month = jan,
doi = "10.1097/MD.0000000000018524",
language = "English",
volume = "99",
journal = "Medicine",
issn = "0025-7974",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "1",
}